Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19141 | 0.98 | TSHR (0.64) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL4204017 | 0.98 | TSHR (0.64) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL719374 | 0.98 | TSHR (0.64) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL7408161 | 0.98 | TSHR (0.64) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL2527082 | 0.98 | TSHR (0.64) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL7407458 | 0.98 | TSHR (0.64) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL9353850 | 0.98 | TSHR (0.64) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL989611 | 0.98 | TSHR (0.64) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL48697 | 0.95 | TSHR (0.75) | TSHRALDH1A1LMNATP53RECQL | |
| SCHEMBL14975 | 0.87 | TSHR (0.88) | TSHRALDH1A1LMNARECQLKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0440329-A1 | S-substituted carbonyl substituted betathioacrylamide biocides and fungicides | ROHM AND HAAS COMPANY (US) | 1991-08-07 | — | — | EP | claimed |
| CN-122055150-A | Cyproheptadine derivatives | 思凯生科股份有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4332086-B1 | COMPOUND OR SALT THEREOF, LIPID PARTICLES, AND PHARMACEUTICAL COMPOSITION | FUJIFILM CORP (JP) | 2026-04-08 | — | — | EP | disclosed |
| EP-4634184-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | Crossfire Oncology Holding B.V. (NL) | 2025-10-22 | — | — | EP | disclosed |
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2025-03-06 | — | — | US | disclosed |
| EP-4448523-A1 | MACROCYCLIC BTK INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| EP-4448521-A1 | REVERSIBLE MACROCYCLIC KINASE INHIBITORS | Crossfire Oncology Holding B.V. (NL) | 2024-10-23 | — | — | EP | disclosed |
| CN-118696041-A | Macrocyclic BTK inhibitors | 克罗斯费尔肿瘤学控股有限公司 | 2024-09-24 | — | — | CN | disclosed |
| WO-2024130526-A1 | A BIOORTHOGONAL CYCLOADDITION REACTION AND USE THEREOF | NANJING UNIVERSITY (CN) | 2024-06-27 | — | — | WO | disclosed |
| WO-2024126617-A1 | BIFUNCTIONAL COMPOUNDS FOR DEGRADING KINASES VIA UBIQUITIN PROTEOSOME PATHWAY | CROSSFIRE ONCOLOGY HOLDING B.V. (NL) | 2024-06-20 | — | — | WO | disclosed |
| EP-0156611-A2 | Intermediates for the preparation of prostaglandin analogues | ONO PHARMACEUTICAL CO., LTD. (JP) | 1985-10-02 | — | — | EP | disclosed |
| US-4536515-A | Substituted phenylalkenoic acids and esters | MERCK FROSST CANADA, INC. (CA) | 1985-08-20 | — | — | US | disclosed |
| EP-0123543-A1 | Leukotriene antagonists, their production and use and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-10-31 | — | — | EP | disclosed |
| US-4453005-A | Process for preparing substituted phenylalkenoic acids | MERCK FROSST CANADA, INC. (CA) | 1984-06-05 | — | — | US | disclosed |
| EP-0104885-A1 | Leukotriene antagonists, their production, and compositions containing them | MERCK FROSST CANADA INC. (CA) | 1984-04-04 | — | — | EP | disclosed |
| EP-0072061-A1 | Amine derivatives, processes for their production and pharmaceutical compositions containing them | FISONS plc (GB) | 1983-02-16 | — | — | EP | disclosed |
| US-4082747-A | CHEMICAL PROCESS | MALLINCKRODT, INC. (US) | 1978-04-04 | — | — | US | disclosed |
| US-4064227-A | Radioimmunoassay method for the determination of cardiotonic glycosides | MALLINCKRODT, INC. (US) | 1977-12-20 | — | — | US | disclosed |
| US-4054740-A | Hydroxybiotin | HOFFMANN-LA ROCHE INC. (US) | 1977-10-18 | — | — | US | disclosed |
| US-4000275-A | BENZIMIDAZO(2,1-B) QUINAZOLIN-12(6H)ONES | ELI LILLY AND COMPANY (US) | 1976-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250074911-A1 | MACROCYCLIC BTK INHIBITORS | BTK, LYN, LCK | TSHR 2394/4885ALDH1A1 4774/4885LMNA 3689/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.